Researchers from the Texas Heart Institute, UTMB, and 7 Hills Pharma have pioneered a groundbreaking study on the use of 7HP349, an oral integrin activator, as a vaccine adjuvant. This research, published in Nature Partner Journal Vaccines, shows how 7HP349 enhances immune responses, with promising applications for Chagas disease and COVID-19 vaccines, particularly in immunocompromised individuals.

7 Hills Pharma launches a COVID-19 vaccine program targeting at-risk elderly, leveraging integrin activator technology to enhance immune responses and improve vaccine effectiveness. Learn more about this breakthrough approach.